Literature DB >> 6252467

The confirmation and maintenance of smallpox eradication.

J G Breman, I Arita.   

Abstract

In December 1979, an independent scientific commission certified global eradication of smallpox. This conclusion was accepted at the 33d World Health Assembly of the World Health Organization (WHO) in May 1980. After WHO's intensified eradication program began in 1967, special certification procedures were used in 35 countries where the disease had been endemic and in 44 others at special risk. Six laboratories are known to retain variola virus; efforts have been made to ensure strict containment of these strains. There is no evidence that smallpox will recur as an endemic disease. Nevertheless, WHO will promote surveillance of smallpox-like disease and selected laboratory research on certain orthopoxviruses. These efforts will maintain confidence that smallpox has been eradicated and confirm that there are no animal reservoirs of variola virus. A more complete understanding of the orthopoxviruses, including monkeypox virus, should also be obtained.

Entities:  

Mesh:

Year:  1980        PMID: 6252467     DOI: 10.1056/NEJM198011273032204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  53 in total

Review 1.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Antitumor effect of the LIVP-GFP recombinant vaccinia virus.

Authors:  I S Petrov; E P Goncharova; I V Kolosova; S G Pozdnyakov; S N Shchelkunov; M A Zenkova; V V Vlasov
Journal:  Dokl Biol Sci       Date:  2013-08-24

3.  Preventive care card for general practice.

Authors:  R Grundy; D M Dwyer
Journal:  J R Coll Gen Pract       Date:  1989-01

4.  Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures.

Authors:  Ilya Lebeau; Graciela Andrei; Fabiana Dal Pozzo; James R Beadle; Karl Y Hostetler; Erik De Clercq; Joost van den Oord; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Maximal sensitive dependence and the optimal path to epidemic extinction.

Authors:  Eric Forgoston; Simone Bianco; Leah B Shaw; Ira B Schwartz
Journal:  Bull Math Biol       Date:  2010-03-30       Impact factor: 1.758

6.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

7.  Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Mark R Deziel; Kris Zager; Qingmei Weng; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Inhibition of monkeypox virus replication by RNA interference.

Authors:  Abdulnaser Alkhalil; Sarah Strand; Eric Mucker; John W Huggins; Peter B Jahrling; Sofi M Ibrahim
Journal:  Virol J       Date:  2009-11-04       Impact factor: 4.099

9.  Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

Authors:  Holger F Rabenau; Ingrid Rapp; Jochen Steinmann
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

Review 10.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.